AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34618202 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (0.1 and 0.2 mg/kg)
Number of subjects: 72
Study 34618202 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 72
Study 34618202 — intervention group
Group type: COMPARATOR
Intervention: Vehicle administration
Number of subjects: 72
Study 32956446 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-month ticagrelor monotherapy following 1-month dual anti-platelet therapy (DAPT)
Number of subjects: 14576
Study 32956446 — intervention group
Group type: COMPARATOR
Intervention: 12-month aspirin monotherapy following 12-month DAPT
Number of subjects: 14576
Study 32956446 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-month ticagrelor monotherapy following 1-month DAPT
Number of subjects: 14576
Study 32956446 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anti-platelet strategies
Number of subjects: 14576
Study 34008425 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative pembrolizumab with chemotherapy (KEYNOTE-866)
Number of subjects: 0
Study 34008425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy (KEYNOTE-905/EV-303)
Number of subjects: 0
Study 34008425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus enfortumab vedotin (KEYNOTE-905/EV-303)
Number of subjects: 0
Study 34008425 — intervention group
Group type: COMPARATOR
Intervention: Radical cystectomy plus pelvic lymph node dissection alone (KEYNOTE-905/EV-303)
Number of subjects: 0
Study 34008425 — intervention group
Group type: COMPARATOR
Intervention: Placebo with chemotherapy (KEYNOTE-866)
Number of subjects: 0
Study 32388527 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery for flap elevation (PFG)
Number of subjects: 20
Study 32388527 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery for osteotomy and odontosection (POG)
Number of subjects: 20
Study 32388527 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (CG)
Number of subjects: 20
Study 35527411 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive biofeedback training combined with oral administration of compound polyethylene glycol 4000-electrolyte powder
Number of subjects: 155
Study 35527411 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of compound polyethylene glycol 4000-electrolyte powder alone
Number of subjects: 155
Study 34517840 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.25 µg/mL)
Number of subjects: 712
Study 34517840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 712
Study 34517840 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 712
Study 32086949 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Doctors (MDs) without dementia at baseline
Number of subjects: 3460
Study 32086949 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 3460
Study 35534628 — intervention group
Group type: EXPERIMENTAL
Intervention: SRR + PACERR
Number of subjects: 40
Study 35534628 — intervention group
Group type: COMPARATOR
Intervention: SRR
Number of subjects: 40
Study 34965860 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO tool (mobile application and web portal)
Number of subjects: 13
Study 35342437 — intervention group
Group type: EXPERIMENTAL
Intervention: Olibanum extract orally disintegrating tablets (ODT), 4 times a day for 3 days
Number of subjects: 50
Study 35342437 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally disintegrating tablets (ODT), 4 times a day for 3 days
Number of subjects: 50
Study 32381556 — intervention group
Group type: EXPERIMENTAL
Intervention: mPATH-CRC (iPad patient decision aid)
Number of subjects: 408
Study 32381556 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 408
Study 32381556 — intervention group
Group type: EXPERIMENTAL
Intervention: mPATH-CRC
Number of subjects: 408
Study 35328871 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 40
Study 35328871 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS)
Number of subjects: 40
Study 35328871 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Strength Training and Electromyostimulation (STEMS)
Number of subjects: 40
Study 35328871 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 40
Study 33208831 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine (0.08 mg/kg) after undisturbed sleep (US)
Number of subjects: 100
Study 33208831 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine (0.08 mg/kg) after forced awakening (FA)
Number of subjects: 100
Study 33208831 — intervention group
Group type: COMPARATOR
Intervention: placebo after undisturbed sleep (US)
Number of subjects: 100
Study 33208831 — intervention group
Group type: COMPARATOR
Intervention: placebo after forced awakening (FA)
Number of subjects: 100
Study 33208831 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine after forced awakening (FA) in females
Number of subjects: 100
Study 33208831 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine after forced awakening (FA) in males
Number of subjects: 100
Study 34565172 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐LIFE (Center‐Based Lifestyle Intervention)
Number of subjects: 140
Study 32409493 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB + ET (combined aerobic and resistance exercise training program)
Number of subjects: 0
Study 32409493 — intervention group
Group type: COMPARATOR
Intervention: RYGB (standard of care)
Number of subjects: 0
Study 35012992 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block (20 mL of 0.5% ropivacaine)
Number of subjects: 45
Study 35012992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate cervical plexus block (20 mL of 0.5% ropivacaine)
Number of subjects: 45
Study 35012992 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep cervical plexus block (20 mL of 0.5% ropivacaine)
Number of subjects: 45
Study 35012992 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 34461584 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention focusing on nutrition, hygiene, and child stimulation, combined with routine health care.
Number of subjects: 511
Study 34461584 — intervention group
Group type: COMPARATOR
Intervention: Routine health care only (Control group).
Number of subjects: 511
Study 33618015 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 36
Study 33618015 — intervention group
Group type: COMPARATOR
Intervention: TTM
Number of subjects: 36
Study 33618015 — intervention group
Group type: COMPARATOR
Intervention: NTC
Number of subjects: 36
Study 33153145 — intervention group
Group type: COMPARATOR
Intervention: No mask
Number of subjects: 14
Study 33153145 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 14
Study 33153145 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloth mask
Number of subjects: 14
Study 35617440 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg aspirin
Number of subjects: 190
Study 35617440 — intervention group
Group type: COMPARATOR
Intervention: 80 mg aspirin
Number of subjects: 190
Study 33509132 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting RV dysfunction including N-terminal pro-brain natriuretic peptide, cardiac troponin I, and ventricular diameter ratios
Number of subjects: 845
Study 32799814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.2 mg/kg)
Number of subjects: 492
Study 32799814 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (2 mg/kg)
Number of subjects: 492
Study 36269141 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis BS50 (2 × 10^9 CFU per day)
Number of subjects: 76
Study 36269141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 32569281 — intervention group
Group type: EXPERIMENTAL
Intervention: Having the kitchen in the same living house
Number of subjects: 369
Study 32569281 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron intake less than 180 tablets
Number of subjects: 369
Study 32569281 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal weight gain during second and third trimester less than 6.53 kg
Number of subjects: 369
Study 32569281 — intervention group
Group type: EXPERIMENTAL
Intervention: Co‐morbidity during pregnancy
Number of subjects: 369
Study 32569281 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm birth
Number of subjects: 369
Study 35255067 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia education
Number of subjects: 135
Study 35255067 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face education
Number of subjects: 135
Study 35255067 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional education)
Number of subjects: 135
Study 34170930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention or metformin (850mg twice daily)
Number of subjects: 317
Study 34170930 — intervention group
Group type: COMPARATOR
Intervention: No treatment (placebo)
Number of subjects: 317
Study 32707429 — intervention group
Group type: EXPERIMENTAL
Intervention: DXP (direct exposure; mares housed adjacent to stallion and allowed direct contact for 2 h for 3 d/wk)
Number of subjects: 21
Study 32707429 — intervention group
Group type: EXPERIMENTAL
Intervention: IXP (indirect exposure; mares housed in an adjacent pen to the stallion but not allowed direct contact)
Number of subjects: 21
Study 32707429 — intervention group
Group type: COMPARATOR
Intervention: CON (control; mares housed away from stallion and not allowed direct or indirect exposure)
Number of subjects: 21
Study 32707429 — intervention group
Group type: EXPERIMENTAL
Intervention: DXP (direct exposure)
Number of subjects: 21
Study 32707429 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 21
Study 35349576 — intervention group
Group type: EXPERIMENTAL
Intervention: PharmQuit (intervention group)
Number of subjects: 156
Study 35349576 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 156
Study 33271498 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 856
Study 33271498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively demanding exercise intervention
Number of subjects: 856
Study 33271498 — intervention group
Group type: COMPARATOR
Intervention: Regular physical education program (Control)
Number of subjects: 856
Study 33271498 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (independently of group)
Number of subjects: 856
Study 36062600 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper and lower Memotain® bonded retainers
Number of subjects: 68
Study 36062600 — intervention group
Group type: COMPARATOR
Intervention: Upper and lower Ortho‐FlexTech™ bonded retainers
Number of subjects: 68
Study 34624173 — intervention group
Group type: EXPERIMENTAL
Intervention: Community ART delivery
Number of subjects: 150
Study 34624173 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based visits
Number of subjects: 150
Study 35870888 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach-back health education (TBHE) based on WeChat mini-programs
Number of subjects: 59
Study 35870888 — intervention group
Group type: COMPARATOR
Intervention: Traditional health education
Number of subjects: 59
Study 34912206 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame intervention group (Dividat Senso, 5 days per week)
Number of subjects: 39
Study 34912206 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame intervention group
Number of subjects: 39
Study 34912206 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rehabilitation treatment)
Number of subjects: 39
Study 32290344 — intervention group
Group type: EXPERIMENTAL
Intervention: RP-G28
Number of subjects: 377
Study 32290344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study 33155484 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise with Kinesio tape
Number of subjects: 120
Study 33155484 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic exercise alone
Number of subjects: 120
Study 32034028 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin 2.5 mg once daily for 8 weeks
Number of subjects: 60
Study 32034028 — intervention group
Group type: COMPARATOR
Intervention: DPP-4 inhibitor
Number of subjects: 60
Study 35728573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively-engaging physical activity (18 sessions)
Number of subjects: 75
Study 35728573 — intervention group
Group type: COMPARATOR
Intervention: Free play (non-cognitively-engaging PA)
Number of subjects: 75
Study 32570700 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 90
Study 32570700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 35250307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided thoracic paravertebral block with 0.33% ropivacaine (T group)
Number of subjects: 60
Study 35250307 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (C group)
Number of subjects: 60
Study 32886828 — intervention group
Group type: EXPERIMENTAL
Intervention: Wu Qin Xi Qigong (WQXQ) exercise
Number of subjects: 0
Study 32886828 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (control group)
Number of subjects: 0
Study 34610600 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0
Study 34610600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34011002 — intervention group
Group type: EXPERIMENTAL
Intervention: SoundBite bone conduction device
Number of subjects: 18
Study 36404985 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum in addition to standard therapy
Number of subjects: 258
Study 36404985 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Ondansetron 4 mg IV intra-operatively)
Number of subjects: 258
Study 34028940 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenohumeral mobilizations
Number of subjects: 121
Study 36265048 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 42
Study 36265048 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 42
Study 32359936 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoemulsion eye drop
Number of subjects: 20
Study 32359936 — intervention group
Group type: COMPARATOR
Intervention: Non-emollient eye drop
Number of subjects: 20
Study 32359936 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoemulsion eye drop (used for 1 month, four times daily)
Number of subjects: 20
Study 32078353 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 673
Study 32078353 — intervention group
Group type: EXPERIMENTAL
Intervention: Inreach (one-on-one education)
Number of subjects: 673
Study 32078353 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach (mailed FIT)
Number of subjects: 673
Study 32078353 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of inreach and outreach
Number of subjects: 673
Study 32343960 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-6379 (25 mg, 75 mg, 150 mg, or 250 mg daily for 4 weeks)
Number of subjects: 57
Study 32343960 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-6379 (any dose)
Number of subjects: 57
Study 32343960 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-6379 (150 mg)
Number of subjects: 57
Study 32343960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 35263680 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day ifenprodil tartrate for 4 weeks
Number of subjects: 10
Study 35263680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 33180816 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (3.25 mg/kg)
Number of subjects: 80
Study 33180816 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 80
Study 35907828 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise program (6 consultations via videoconference, 50–75 min each, ketogenic very low‐calorie diet with meal replacements)
Number of subjects: 88
Study 35907828 — intervention group
Group type: COMPARATOR
Intervention: Exercise program (6 consultations via videoconference, 20–30 min each, strengthening exercise program, physical activity plan, educational/exercise resources)
Number of subjects: 88
Study 34028042 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertiveness training through hybrid education model
Number of subjects: 0
Study 34028042 — intervention group
Group type: COMPARATOR
Intervention: Control group (no assertiveness training)
Number of subjects: 0
Study 32928957 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg once daily
Number of subjects: 191
Study 32928957 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg once daily
Number of subjects: 191
Study 32928957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 36161964 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-test kit
Number of subjects: 376
Study 33298117 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily use of the Insight Timer meditation app for 10 minutes daily for 30 days
Number of subjects: 150
Study 33298117 — intervention group
Group type: COMPARATOR
Intervention: Control group (no usage of meditation app)
Number of subjects: 150
Study 35121137 — intervention group
Group type: EXPERIMENTAL
Intervention: Two additional intensive oral hygiene appointments before and after GA
Number of subjects: 408
Study 35121137 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group) without additional appointments
Number of subjects: 408
Study 33719774 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative ureteral stenting (n = 24, 31.6%)
Number of subjects: 76
Study 33719774 — intervention group
Group type: COMPARATOR
Intervention: No perioperative ureteral stenting (n = 52, 68.4%)
Number of subjects: 76
Study 35218064 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Centered Cognitive Development Support Program
Number of subjects: 30
Study 35218064 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 32833560 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor blockade using exendin-(9,39)
Number of subjects: 0
Study 32833560 — intervention group
Group type: COMPARATOR
Intervention: Weight-matched controls
Number of subjects: 0
Study 34228974 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve repair (AVr)
Number of subjects: 417
Study 34228974 — intervention group
Group type: COMPARATOR
Intervention: Aortic valve replacement (AVR)
Number of subjects: 417
Study 34196903 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated concentric resistance exercise (CON) 3/week for 8 weeks
Number of subjects: 37
Study 34196903 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated eccentric resistance exercise (ECC) 3/week for 8 weeks
Number of subjects: 37
Study 34196903 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated concentric resistance exercise (CON)
Number of subjects: 37
Study 34196903 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated eccentric resistance exercise (ECC)
Number of subjects: 37
Study 36199780 — intervention group
Group type: COMPARATOR
Intervention: Hormone group (prednisone acetate, n = 34)
Number of subjects: 64
Study 36199780 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (Ginkgo‐Damole combined with prednisone acetate, n = 30)
Number of subjects: 64
Study 36199780 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 64
Study 36199780 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study 36420979 — intervention group
Group type: EXPERIMENTAL
Intervention: R40/E10
Number of subjects: 452
Study 36420979 — intervention group
Group type: EXPERIMENTAL
Intervention: R20/E10
Number of subjects: 452
Study 36420979 — intervention group
Group type: COMPARATOR
Intervention: R10/E10
Number of subjects: 452
Study 36420979 — intervention group
Group type: COMPARATOR
Intervention: R40
Number of subjects: 452
Study 36420979 — intervention group
Group type: COMPARATOR
Intervention: R20
Number of subjects: 452
Study 34902182 — intervention group
Group type: EXPERIMENTAL
Intervention: In-phase theta tACS
Number of subjects: 0
Study 34902182 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study 34393856 — intervention group
Group type: EXPERIMENTAL
Intervention: Single infusion of ketamine
Number of subjects: 32
Study 34393856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 34393856 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HR
Number of subjects: 32
Study 34393856 — intervention group
Group type: EXPERIMENTAL
Intervention: HR during the night (2-3 a.m.)
Number of subjects: 32
Study 35728658 — intervention group
Group type: EXPERIMENTAL
Intervention: Etripamil 70 mg (up to 2 doses separated by 10 minutes)
Number of subjects: 500
Study 35728658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 35728658 — intervention group
Group type: EXPERIMENTAL
Intervention: Etripamil 70 mg
Number of subjects: 500
Study 34968107 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (blood alcohol concentration [BAC] = .075%)
Number of subjects: 135
Study 34968107 — intervention group
Group type: COMPARATOR
Intervention: Water control
Number of subjects: 135
Study 32568929 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphakia with contact lens correction
Number of subjects: 57
Study 32568929 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphakia with spectacles
Number of subjects: 57
Study 32568929 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphakia with no correction
Number of subjects: 57
Study 32568929 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphakia (overall)
Number of subjects: 57
Study 32568929 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphakic eyes
Number of subjects: 57
Study 32335316 — intervention group
Group type: EXPERIMENTAL
Intervention: SBAR-based program
Number of subjects: 54
Study 32335316 — intervention group
Group type: COMPARATOR
Intervention: Handoff group
Number of subjects: 54